300 related articles for article (PubMed ID: 27183521)
1. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S19-26. PubMed ID: 27183521
[TBL] [Abstract][Full Text] [Related]
2. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e19-e26. PubMed ID: 27755239
[TBL] [Abstract][Full Text] [Related]
3. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
Maurea N; Spallarossa P; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1(Suppl 1):S93-S104. PubMed ID: 27183530
[TBL] [Abstract][Full Text] [Related]
4. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors.
Tocchetti CG; Gallucci G; Coppola C; Piscopo G; Cipresso C; Maurea C; Giudice A; Iaffaioli RV; Arra C; Maurea N
Eur J Heart Fail; 2013 May; 15(5):482-9. PubMed ID: 23325019
[TBL] [Abstract][Full Text] [Related]
5. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management.
Sundararajan S; Kumar A; Poongkunran M; Kannan A; Vogelzang NJ
Future Oncol; 2016; 12(8):1067-80. PubMed ID: 26901457
[TBL] [Abstract][Full Text] [Related]
7. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
Maurea N; Spallarossa P; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e93-e104. PubMed ID: 27755247
[TBL] [Abstract][Full Text] [Related]
8. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
[TBL] [Abstract][Full Text] [Related]
9. Genetic and ethnic modulation of cardiovascular toxicity of vascular endothelial growth factor inhibitors.
Chen YC; Chung CC; Lin YK; Chen YJ
Ann Med; 2018 Feb; 50(1):46-56. PubMed ID: 28929822
[TBL] [Abstract][Full Text] [Related]
10. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy.
De Keulenaer GW; Doggen K; Lemmens K
Circ Res; 2010 Jan; 106(1):35-46. PubMed ID: 20056944
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis.
Abdel-Qadir H; Ethier JL; Lee DS; Thavendiranathan P; Amir E
Cancer Treat Rev; 2017 Feb; 53():120-127. PubMed ID: 28104567
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.
Albini A; Pennesi G; Donatelli F; Cammarota R; De Flora S; Noonan DM
J Natl Cancer Inst; 2010 Jan; 102(1):14-25. PubMed ID: 20007921
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
Kruzliak P; Novák J; Novák M
Am J Hypertens; 2014 Jan; 27(1):3-13. PubMed ID: 24168915
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxic effects of angiogenesis inhibitors.
Dobbin SJH; Petrie MC; Myles RC; Touyz RM; Lang NN
Clin Sci (Lond); 2021 Jan; 135(1):71-100. PubMed ID: 33404052
[TBL] [Abstract][Full Text] [Related]
16. [Renal toxicity of anti-VEGF (corrected) targeted therapies].
Vigneau C; Rioux-Leclercq N
Nephrol Ther; 2013 Jun; 9(3):174-9. PubMed ID: 23410950
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
Fedele C; Riccio G; Malara AE; D'Alessio G; De Lorenzo C
Breast Cancer Res Treat; 2012 Jul; 134(2):595-602. PubMed ID: 22674190
[TBL] [Abstract][Full Text] [Related]
18. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.
Hall PS; Harshman LC; Srinivas S; Witteles RM
JACC Heart Fail; 2013 Feb; 1(1):72-8. PubMed ID: 24621801
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiology of anthracycline cardiotoxicity.
Mele D; Tocchetti CG; Pagliaro P; Madonna R; Novo G; Pepe A; Zito C; Maurea N; Spallarossa P
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S3-S11. PubMed ID: 27183523
[TBL] [Abstract][Full Text] [Related]
20. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
Steingart RM; Bakris GL; Chen HX; Chen MH; Force T; Ivy SP; Leier CV; Liu G; Lenihan D; Lindenfeld J; Maitland ML; Remick SC; Tang WH
Am Heart J; 2012 Feb; 163(2):156-63. PubMed ID: 22305831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
